VERACYTE, INC. Impairment of Intangible Assets, Finite-lived
VERACYTE, INC. (VCYT) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-02-26
- VERACYTE, INC. impairment of intangible assets, finite-lived for the quarter ending 2024-12-31 was $2.09M, a 93.18% decline year-over-year.
- VERACYTE, INC. impairment of intangible assets, finite-lived for the quarter ending 2024-09-30 was $185.00K, a 99.47% decline year-over-year.
- VERACYTE, INC. impairment of intangible assets, finite-lived for the quarter ending 2024-06-30 was $0.00.
- VERACYTE, INC. impairment of intangible assets, finite-lived for the quarter ending 2024-03-31 was $429.00K, a 69.57% decline year-over-year.
- VERACYTE, INC. impairment of intangible assets, finite-lived for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- VERACYTE, INC. impairment of intangible assets, finite-lived for fiscal 2024 was $2.70M, a 95.96% decline from fiscal 2023.
- VERACYTE, INC. impairment of intangible assets, finite-lived for fiscal 2023 was $66.90M, a 1927.27% increase from fiscal 2022.
- VERACYTE, INC. impairment of intangible assets, finite-lived for fiscal 2022 was $3.30M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.27M derived: sum of 2 quarters · filed 2026-02-26 | $2.27M derived: sum of 3 quarters · filed 2026-02-26 | $2.70M 10-K · filed 2026-02-26 |
| 2024-09-30 | $185.00K 10-Q · filed 2024-11-07 | $185.00K derived: sum of 2 quarters · filed 2024-11-07 | $614.00K 10-Q · filed 2024-11-07 | $31.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $429.00K 10-Q · filed 2024-08-07 | $31.02M derived: sum of 3 quarters · filed 2026-02-26 | $65.92M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $429.00K 10-Q · filed 2024-05-08 | $31.02M derived: sum of 2 quarters · filed 2026-02-26 | $65.92M derived: sum of 3 quarters · filed 2026-02-26 | $65.92M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $30.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $65.49M derived: sum of 2 quarters · filed 2026-02-26 | $65.49M derived: sum of 3 quarters · filed 2026-02-26 | $66.90M 10-K · filed 2026-02-26 |
| 2023-09-30 | $34.90M 10-Q · filed 2024-11-07 | $34.90M derived: sum of 2 quarters · filed 2024-11-07 | $36.31M 10-Q · filed 2024-11-07 | $36.29M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $1.41M 10-Q · filed 2024-08-07 | $1.39M derived: sum of 3 quarters · filed 2025-02-28 | $1.39M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.41M 10-Q · filed 2024-05-08 | $1.39M derived: sum of 2 quarters · filed 2025-02-28 | $1.39M derived: sum of 3 quarters · filed 2025-02-28 | |
| 2022-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$18.00K derived: sum of 2 quarters · filed 2025-02-28 | $3.30M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $3.32M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $3.32M 10-Q · filed 2022-08-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-22 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-25 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |